Primary Mesangial Proliferative Glomerulonephritis: The Forgotten Glomerulopathy.
- 1Division of Nephrology, Department of Medicine, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA.
- 2Department of Pathology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA.
Abstract
Primary mesangial proliferative glomerulonephritis (MesPGN) refers to the light microscopic description of increased mesangial cells (greater than three cells per mesangial area) without endocapillary proliferation, necrosis, and crescents in the absence of another primary glomerulopathy (e.g., IgA nephropathy) or systemic illness (e.g., lupus). Immunofluorescence may be negative or contain mesangial IgM +/- complement (IgM nephropathy) or C1q + immunoglobulin (C1q nephropathy). The presence of either immune deposits or mesangial proliferation per se connotes a worse prognosis when compared with minimal changes. Segmental sclerosis may be present and imparts a worse prognosis regardless of mesangial proliferation or immune deposits. Primary MesPGN may present clinically as nephrotic syndrome, non-nephrotic proteinuria +/- hematuria, or isolated hematuria. If nephrotic, MesPGN may be considered nosologically as a primary podocytopathy with secondary mesangial cell activation, especially when immunofluorescence is negative. Such podocyte injury may be driven by circulating factors and/or antibodies directed against podocyte-specific antigens. Alternatively, IgM or complement deposits suggest an antibody-driven immune-complex etiology primarily affecting the mesangium with secondary podocyte injury analogous to IgA nephropathy, especially when presenting as non-nephrotic proteinuria or hematuria. No randomized controlled trials have addressed immunosuppression in primary MesPGN. If non-nephrotic or isolated hematuria, supportive care is indicated. If nephrotic, initial immunosuppression should mimic that of the primary podocytopathies (high-dose oral steroids), although tacrolimus may substitute if there is a concern for steroid toxicity. For frequently relapsing/steroid-dependent cases, rituximab is our choice for adults, probably with maintenance dosing. Steroid-resistant cases may be treated with calcineurin inhibition.
Related
- Real-World Outcomes of Iptacopan in C3 Glomerulopathy and Primary Immune Complex–Mediated Membranoproliferative Glomerulonephritis
- P093 Primary Sjögren syndrome complicated by type II cryoglobulinaemic vasculitis, immune-complex membranoproliferative glomerulonephritis, and bowel perforation in an elderly woman
- Salvaging the forgotten valve: T-TEER as the new frontier in torrential primary TR
- Case Report: A case of early rapid recurrence of a primary intracranial alveolar soft part sarcoma with high proliferative activity and complex molecular variations
- Collapsing Glomerulopathy Encountered in Time Zero Kidney Allograft Biopsies
BibTeX
@article{filippone2026primary,
title = {{Primary Mesangial Proliferative Glomerulonephritis: The Forgotten Glomerulopathy.}},
author = {Edward J Filippone and John L Farber},
journal = {Antibodies (Basel, Switzerland)},
year = {2026},
month = oct,
doi = {10.3390/antib15050096},
url = {https://europepmc.org/article/MED/42930038},
note = {CC BY},
}
RIS
TY - JOUR
TI - Primary Mesangial Proliferative Glomerulonephritis: The Forgotten Glomerulopathy.
AU - Edward J Filippone
AU - John L Farber
PY - 2026
DA - 2026/10/12
JO - Antibodies (Basel, Switzerland)
DO - 10.3390/antib15050096
UR - https://europepmc.org/article/MED/42930038
AB - Primary mesangial proliferative glomerulonephritis (MesPGN) refers to the light microscopic description of increased mesangial cells (greater than three cells per mesangial area) without endocapillary proliferation, necrosis, and crescents in the absence of another primary glomerulopathy (e.g., IgA nephropathy) or systemic illness (e.g., lupus). Immunofluorescence may be negative or contain mesangial IgM +/- complement (IgM nephropathy) or C1q + immunoglobulin (C1q nephropathy). The presence of either immune deposits or mesangial proliferation per se connotes a worse prognosis when compared with minimal changes. Segmental sclerosis may be present and imparts a worse prognosis regardless of mesangial proliferation or immune deposits. Primary MesPGN may present clinically as nephrotic syndrome, non-nephrotic proteinuria +/- hematuria, or isolated hematuria. If nephrotic, MesPGN may be considered nosologically as a primary podocytopathy with secondary mesangial cell activation, especially when immunofluorescence is negative. Such podocyte injury may be driven by circulating factors and/or antibodies directed against podocyte-specific antigens. Alternatively, IgM or complement deposits suggest an antibody-driven immune-complex etiology primarily affecting the mesangium with secondary podocyte injury analogous to IgA nephropathy, especially when presenting as non-nephrotic proteinuria or hematuria. No randomized controlled trials have addressed immunosuppression in primary MesPGN. If non-nephrotic or isolated hematuria, supportive care is indicated. If nephrotic, initial immunosuppression should mimic that of the primary podocytopathies (high-dose oral steroids), although tacrolimus may substitute if there is a concern for steroid toxicity. For frequently relapsing/steroid-dependent cases, rituximab is our choice for adults, probably with maintenance dosing. Steroid-resistant cases may be treated with calcineurin inhibition.
SN - 2073-4468
ER -